Brokerages Expect Galectin Therapeutics Inc. (GALT) to Post -$0.11 Earnings Per Share

Brokerages predict that Galectin Therapeutics Inc. (NASDAQ:GALT) will report earnings of ($0.11) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Galectin Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.11) and the lowest estimate coming in at ($0.12). Galectin Therapeutics posted earnings of ($0.13) per share during the same quarter last year, which would suggest a positive year over year growth rate of 15.4%. The firm is expected to announce its next earnings results on Tuesday, March 27th.

According to Zacks, analysts expect that Galectin Therapeutics will report full-year earnings of ($0.53) per share for the current fiscal year, with EPS estimates ranging from ($0.53) to ($0.52). For the next fiscal year, analysts expect that the business will report earnings of ($0.48) per share, with EPS estimates ranging from ($0.60) to ($0.35). Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that that provide coverage for Galectin Therapeutics.

Galectin Therapeutics (NASDAQ:GALT) last issued its earnings results on Tuesday, November 7th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.02.

GALT has been the topic of a number of recent research reports. Zacks Investment Research upgraded shares of Galectin Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a report on Thursday, November 30th. ValuEngine lowered shares of Galectin Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. Roth Capital initiated coverage on shares of Galectin Therapeutics in a report on Thursday, October 19th. They set a “buy” rating and a $8.00 price target on the stock. Seaport Global Securities reiterated a “buy” rating and set a $5.00 price target on shares of Galectin Therapeutics in a report on Friday, October 6th. Finally, HC Wainwright lifted their price target on shares of Galectin Therapeutics from $3.50 to $6.00 and gave the stock a “buy” rating in a report on Tuesday, November 28th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $4.55.

Shares of Galectin Therapeutics (NASDAQ:GALT) traded down $0.05 during trading on Thursday, reaching $2.44. 321,249 shares of the company’s stock were exchanged, compared to its average volume of 435,412. Galectin Therapeutics has a 1 year low of $0.88 and a 1 year high of $3.68.

A number of hedge funds have recently added to or reduced their stakes in the stock. Advisor Group Inc. lifted its holdings in Galectin Therapeutics by 7.4% in the third quarter. Advisor Group Inc. now owns 519,850 shares of the company’s stock valued at $1,112,000 after buying an additional 35,850 shares during the period. Virtu KCG Holdings LLC lifted its holdings in Galectin Therapeutics by 24.4% in the second quarter. Virtu KCG Holdings LLC now owns 107,203 shares of the company’s stock valued at $264,000 after buying an additional 21,008 shares during the period. Vanguard Group Inc. lifted its holdings in Galectin Therapeutics by 18.2% in the second quarter. Vanguard Group Inc. now owns 871,510 shares of the company’s stock valued at $2,144,000 after buying an additional 134,165 shares during the period. Finally, Northern Trust Corp lifted its holdings in Galectin Therapeutics by 4.4% in the second quarter. Northern Trust Corp now owns 75,097 shares of the company’s stock valued at $185,000 after buying an additional 3,176 shares during the period. Institutional investors and hedge funds own 11.07% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was first posted by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/3094485/brokerages-expect-galectin-therapeutics-inc-galt-to-post-0-11-earnings-per-share.html.

About Galectin Therapeutics

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.

Get a free copy of the Zacks research report on Galectin Therapeutics (GALT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Galectin Therapeutics (NASDAQ:GALT)

Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.